Concepedia

Paul Meyvisch

PM

Statistics

Publications

16

Citations

3K

H-Index

14

Active since

2007

Affiliations

Janssen (Belgium)(Current)

KU Leuven

Stellenbosch University

Amsterdam UMC Location University of Amsterdam

Janssen (United States)

Paul Meyvisch is an author at Janssen (Belgium) specializing in pharmacology, clinical pharmacology, and pharmacotherapy.

ORCID

Publications per year

2007–2019

16

Publications

16

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch et al. · New England Journal of Medicine · 2009 · 839 citations · Full text

, , +14

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch et al. · New England Journal of Medicine · 2014 · 752 citations · Full text

, , +14

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

Andreas H. Diacon, Peter R. Donald, Alexander S. Pym et al. · Antimicrobial Agents and Chemotherapy · 2012 · 380 citations · Full text

, , +13

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

Alexander S. Pym, Andreas H. Diacon, Shenjie Tang et al. · European Respiratory Journal · 2015 · 341 citations · Full text

, , +14

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

S. Noachtar, E. Andermann, Paul Meyvisch et al. · Neurology · 2008 · 244 citations

, , +16

1–5 of 16